Zhejiang Wecome Pharmaceutical Co Ltd

Zhejiang Wecome Pharmaceutical has a current ratio of 2.07, indicating moderate liquidity, but its free cash flow is negative at -262.45 million CNY, and capital expenditures are -67.17 million CNY, suggesting ongoing investment in operations. The company's debt-to-equity ratio is 0.18, reflecting a relatively conservative capital structure, though its net cash position is negative after subtracting total debt. The company's profitability is weak, with a return on equity of -24.97% and a return on assets of -18.17%, both significantly below the industry median for pharmaceutical firms. This underperformance is driven by a net loss of 227.34 million CNY and an operating loss of 201.09 million CNY, despite a gross profit of 40.23 million CNY. Zhejiang Wecome's revenue is concentrated in the domestic market, with no disclosed international operations. The company's product portfolio includes Chinese patent medicines and Western formulations, but no segment-specific revenue breakdown is available. This lack of diversification increases exposure to domestic regulatory and economic shifts. The company's growth trajectory is uncertain, with no disclosed revenue growth or decline in the current fiscal year. Historical revenue of 225.27 million CNY is flat compared to prior periods, and no forward-looking guidance is provided. The absence of clear growth drivers or market expansion plans limits visibility. Risk factors include liquidity constraints, with negative free cash flow and a net cash deficit, and potential dilution from future equity issuance, though current dilution risk is assessed as low. The company's operating cash flow of 67.09 million CNY provides some buffer, but it is insufficient to cover debt obligations or fund growth. Recent filings and transcripts are not available in the input data, so no specific events can be cited. However, the company's financial performance and risk profile suggest a need for close monitoring of its cash flow management and strategic direction.